Use of isomalto-oligosaccharide in the treatment of lipid profiles and constipation in hemodialysis patients

Journal of Renal Nutrition

Volumn 11, Issue 2, 2001, Pages 73-79

  Wang, Hsueh Fang ^a   Lim, Paik Seong ^b   Kao, Mei Ding ^c   Chan, Elsie C ^b   Lin, Lung Chin ^b   Wang, Nan Phong ^a  

^a HUNGKUANG UNIVERSITY   (Taiwan)

^b KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^c PROVIDENCE UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; OLIGOSACCHARIDE;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CONSTIPATION; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; QUESTIONNAIRE; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONSTIPATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; QUESTIONNAIRES; RENAL DIALYSIS;

EID: 0035316850     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/jren.2001.22485     Document Type: Article

References (47)

1. Lundin AP, Adler AJ, Feinroth MV, et al: Maintenance hemodialysis: Survival beyond the first decade. JAMA 244:38-40, 1980
2. Disney APS (ed): ANZDATA Report 1995. Adelaide, South Australia, Australia, and New Zealand Dialysis and Transplant Registry, 1995
3. US Renal Data Systems: USRDS 1993 Annual Data Report. Bethesda, MD, The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1993, pp 49-54
4. Green D, Stone NJ, Krumlovsky FA: Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovasc Dis 26:133-144, 1983
5. Lindner A, Charra B, Sherrard DJ, et al: Accelerated atherosclerosis on prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1980
6. Cheung AK, Wu LL, Kabilitz C, et al: Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271-276, 1993
7. Avram MM, Goldwasser P, Burrell DE, et al: The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 20:324-325, 1992
8. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32:S142-156, 1998 (suppl 3)
9. Rubies-Prat J, Espinel E, Joven J, et al: High density lipoprotein subfractions in chronic uremia. Am J Kidney Dis 9:60-65, 1987
10. Senti M, Romero R, Pedro-Botet J, et al: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41:1394-1399, 1992
11. Monzani G, Bergesio F, Ciuti R, et al: Lipoprotein abnormalities in chronic renal failure and dialysis patients. Blood Purif 14:262-272, 1996
12. Attman P-O, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-Relation to renal function and dialysis. Nephron 57:401-410, 1991
13. Parsy D, Dracon M, Cachera C, et al: Lipoprotein abnormalities in chronic hemodialysis patients. Nephrol Dial Transplant 3:51-56, 1988
14. Senti M, Romero R, Pedro-Botet J, et al: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41:1394-1399, 1992
15. Attman P-O, Alaupovic P, Gustafson A: Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 32:368-375, 1987
16. Bergesio F, Monzani G, Ciuti R, et al: Lipids and apolipoproteins changes during the progression of chronic renal failure. Clin Nephrol 38:264-270, 1992
17. St Peter SL, Clark JL, Levos OM: Drug therapy in hemodialysis patients. Special considerations in the elderly. Drugs Aging 12:441-459, 1998
18. Odaka K, Inamoto H, Sata K, et al: Constipation and dietary fiber in dialysis patients. J Jpn Soc Dial Ther 22:995-998, 1989
19. 13C-isomaltooligosaccharides in healthy men. Biosci Biotechnol Biochem 56:937-940, 1992
20. Kohmoto T, Fukui F, Takaku H, et al: Dose-response test of isomaltooligosaccharides for increasing fecal bifidobacteria. Agric Biol Chem 55:2157-2159, 1991
21. Nakakuki T: Properties and uses of oligosaccharides. Oyo Tohtsu 42:275-283, 1995
22. Yaeshima T: Benefits of bifidobacteria to human health. Bull Int Dairy Fed 313:36-42, 1996
23. Mitsuoka T: Bifidobacteria and their role in human health. J Ind Microbiol 6:263-268, 1990
24. Hughes DB, Hoover DG: Bifidobacteria: Their potential for use in American dairy products. Food Technol 45:74-83, 1991
25. Kohmoto T, Fukui F, Takaku H, et al: Effect of Isomaltooligosaccharides on human fecal flora. Bifidobacteria Microflora 7:61-69, 1988
26. Kaneko T, Kohmoto T, Kikuch H, et al: Digestibility of isomaltooligosaccharides by rats and effect on serum lipids. Nippon Nogeikagaku Kaishi 66:1211-1220, 1992
27. Hidaka H, Yasuhito T, Eida T: Proliferation of bidfidobacteria by oligosaccharides and their useful on human health. Bifidobacteria Microflora 10:65-79, 1991
28. Yang Y, Tsai CE: Effect of biosynthetic in digestible carbohydrates on digestion and lipid metabolism in rats. Food Sci 20:215-228, 1993
29. Whitehead WE, Chaussade S, Corazziari E, et al: Report of an international workshop on management of constipation. Gastroenterology 4:99-113, 1991
30. Hughes DB, Hoover DG: Bifidobacteria: Their potential for use in American dairy products. Food Technol 45:74-83, 1991
31. Johnson W, Daugirdas JT, Ing TS (eds): Handbook of Dialysis (ed 2). Boston, MA, Little, Brown, 1994, pp 623-624
32. Yasuda G, Takeshita Y, Kimura T, et al: Constipation occurs less frequently in CAPD patients than in HD patients. Perit Dial Int 15:283-292, 1995
33. Hidaka H, Eida T, Takizawa T, et al: Effects of fructooligosaccharides on intestinal flora and human health. Bifidobacteria Microflora 5:37-50, 1986
34. Liu S, Lin Y, Tsai CE: Biotechnically synthesized oligosaccharides and polydextrose reduce constipation and putrefactive metabolites in the human. J Chin Nutr Soc 19:221-232, 1994
35. Tanaka R, Shimosaka K: Investigation of stool frequency in elderly who are bedridden and its improvement by ingesting of bifidus yogurt. Jpn Geriatr 19:577-586, 1982
36. Corazziari E, Bausano G, Torsoli A, et al: Italian cooperative study on chronic constipation, in Wienbeck M (ed): Motility of the Digestive Tract. New York, NY, Raven, 1982, pp 523-525
37. Mitsuoka T, Hidaka H, Eida T: Effect of fructooligosaccharides in intestinal microflora. Die Nahrung 31:5-6, 1987
38. Kok N, Roberfroid M, Robert A, et al: Involvement of lipogenesis in lower VLDL secretion induced by oligofructose in rats. Br J Nutr 76:881-890, 1996
39. Levrat M, Favier M, Moundras C, et al: Role of dietary propionic acid and bile acid secretion in the hypocholesterolemic effects of oligosaccharides in rats. J Nutr 124:531-539, 1994
40. Homma N: Bifidobacteria as a resistance factor in human beings. Bifidobacteria Microflora 7:35-42, 1988
41. Fingegold SM, Sutter VL, Mathisen GE: Normal indigenous flora, in Hentges DJ (ed): Human Intestinal Microflora in Health and Disease. New York, NY, Academic, 1983, pp 3-31
42. Yamashita K, Kawai K, Itakura M: Effects of fructose-oligosaccharides on blood glucose and serum lipids in diabetic subjects. Nutr Res 4:961-966, 1984
43. Schaafsma G, Meuling WJ, van Dokkum W, et al: Effects of a milk product, fermented by Lactobaccilus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers. Eur J Clin Nutr 52:436-440, 1998
44. Thea A, Canavese C, Manhiarotti J, et al: Three-year followup after withdrawal of iron therapy in uremic patients on regular dialytic treatment. Res Clin Lab 16:517-522, 1986
45. MacDougallJC, Hutton RD, Cavill I, et al: Poor response to treatment of renal anemia with erythropoietin corrected by iron given intravenously. BMJ 299:157-158, 1989
46. Golubov J, Flanagan P, Adams P: Inhibition of iron absorption by omeprozole in a rat model. Dig Dis Sci 36:405-408, 1991
47. Rasic J, Kurmann J: Bifidobacteria and their role. Basel, Switzerland, Birkhauser Verlag Basel, 1983